your market intelligence analyst
Search Results
63 results
Your search is now limited to «FDA Actions» expert search.
PMLiVE 11/15/2019 05:50
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 16-0 to recommend the expansion of Vascepa (icosapent ethyl) to reduce the risk of cardiovascular events, such as heart attacks and stroke, in high-risk patients.
More from PMLiVE:
GlobeNewswire 11/14/2019 17:34
The FDA has not reviewed the information herein or determined whether to approve Vascepa for use to reduce the risk of major adverse cardiovascular events as studied in REDUCE-IT.
More from GlobeNewswire:
PR Newswire 11/04/2019 07:00
The proposed indication to be discussed at this upcoming CRDAC meeting is for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adult patients.
More from PR Newswire:
Business Wire 10/26/2019 09:15
The FDA’s letters to health care providers earlier this year have helped Abiomed and the post-approval study principal investigators educate other medical providers on the importance of using simple identifiers to achieve timely identification of right side heart failure in the catheterization lab and ICU,” said Seth Bilazarian, MD, the chief medical officer of Abiomed ...
More from Business Wire:
Cardiac Rhythm News 10/22/2019 11:19
The US Food and Drug Administration (FDA) has approved Farxiga (dapaglifozin, AstraZeneca) to reduce the risk of hospitalisation for heart failure in adults with type 2 diabetes and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
More from Cardiac Rhythm News:
AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors ...
More from Pharmaceutical Business Review:
Healio News 10/21/2019 10:03
In DAPA-HF, dapagliflozin added to standard therapy for heart failure was associated with reduced risk for worsening heart failure and CV death for patients with heart failure with and without diabetes.
More from Healio News:
ENDPOINTS 10/21/2019 08:55
The results showed that the Farxiga treatment did trigger a lower rate of hospitalization for heart failure — but the therapy was not better or worse than placebo in its impact on the rate of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke.
More from ENDPOINTS: 10/20/2019 22:10
This is promising news for the 30 million people living with type 2 diabetes in the US, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke.
More from

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications